[1]邵文博,李韬芝,周琼,等.活血化瘀法联合化疗治疗中晚期胃癌Meta分析[J].西部中医药,2024,37(09):91-95.[doi:10.12174/j.issn.2096-9600.2024.09.20]
　SHAO Wenbo,LI Taozhi,ZHOU Qiong,et al.Meta-analysis: Activating-blood Resolving-stasis Method Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2024,37(09):91-95.[doi:10.12174/j.issn.2096-9600.2024.09.20]
点击复制

活血化瘀法联合化疗治疗中晚期胃癌Meta分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年09期
页码:
91-95
栏目:
二次研究
出版日期:
2024-09-15

文章信息/Info

Title:
Meta-analysis: Activating-blood Resolving-stasis Method Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer
作者:
邵文博1,2,3, 李韬芝1,3, 周琼1, 王玉坤1,3, 程志强3
1.北京中医药大学，北京 100029
2.中国中医科学院广安门医院，北京 100053
3.中日友好医院，北京 100029
Author(s):
SHAO Wenbo1,2,3, LI Taozhi1,3, ZHOU Qiong1, WANG Yukun1,3, CHENG Zhiqiang3
1.Beijing University of Chinese Medicine, Beijing 100029, China
2.Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
3.China-Japan Friendship Hospital, Beijing 100029, China
关键词:
中晚期胃癌; 活血化瘀; 中医疗法; 化疗; Meta分析
Keywords:
advanced gastric cancer; activating-blood resolving-stasis method; TCM therapy; chemotherapy; Meta analysis
分类号:
R273
DOI:
10.12174/j.issn.2096-9600.2024.09.20
文献标志码:
A
摘要:
目的系统评价活血化瘀法联合化疗治疗中晚期胃癌的疗效及安全性。 方法检索中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、中文科技期刊全文数据库（VIP）及PubMed、EMbase等数据库，按照纳入、排除标准由两位研究者独立筛选和提取资料，采用R软件进行Meta分析。 结果共纳入10项研究，735例患者。Meta分析结果显示：活血化瘀法联合化疗治疗中晚期胃癌在提高近期有效率（OR=0.49，95%CI：0.28～0.85，P＜0.01）和总有效率（OR=0.43，95%CI：0.29～0.65，P＜0.01），改善患者卡氏评分（SMD=1.42，95%CI：1.17～1.68，P＜0.01），减少患者不良反应发生率，包括白细胞下降发生率（OR=0.27，95%CI：0.17～0.41，P＜0.01）、恶心发生率（OR=0.43，95%CI：0.25～0.75，P＜0.01）、外周神经毒性发生率（OR=0.53，95%CI：0.29～0.96，P＜0.05），改善肝功能（OR=0.44，95%CI：0.25～0.79，P＜0.01），改善免疫指标，包括NK（SMD=0.79，95%CI：0.45～1.12，P＜0.01）、CD3（SMD=1.68，95%CI：1.40～1.95，P＜0.01）、CD8（SMD=-0.40，95%CI：-0.64～-0.15，P＜0.01）、CD4（SMD=-0.45，95%CI：-0.73～-0.18，P＜0.01）、CD4/CD8（SMD=-0.52，95%CI：-0.85～-0.20，P＜0.01）方面具有疗效优势，优于单纯化疗组，差异具有统计学意义（P＜0.01）。 结论活血化瘀法联合化疗治疗中晚期胃癌，在提高临床疗效，改善免疫状况和减少不良反应方面均优于常规疗法。
Abstract:
ObjectiveTo systematically assess clinical effects and the safety of activating-blood resolving-stasis method joined with chemotherapy in the treatment of advanced gastric cancer. MethodsThe literature was searched from CNKI, CBM, VIP, PubMed and EMbase, and the data was screened and extracted by two researchers independently according to the inclusion and exclusion standard, R software was used to perform Meta analysis. ResultsThe study has included ten studies and 735 patients. Meta analysis results showed that: activating-blood resolving-stasis method joined with chemotherapy in the treatment of advanced gastric cancer had the advantages in lifting short-term effective rate (OR=0.49, 95%CI:0.28~0.85, P<0.01) and total effective rate (OR=0.43, 95%CI:0.29~0.65, P<0.01), improving Karnofsky scores (SMD=1.42, 95%CI:1.17~1.68, P<0.01), lowering the patients' incidences of adverse reactions, incluing the incidence of leukocyte decline (OR=0.27, 95%CI:0.17~0.41, P<0.01), the incidence of nausea (OR=0.43, 95%CI:0.25~0.75, P<0.01), the incidence of peripheral neurotoxicity (OR=0.53, 95%CI:0.29~0.96, P<0.05), improving liver function (OR=0.44, 95%CI:0.25~0.79, P<0.01), improving immune indicators, including NK (SMD=0.79, 95%CI:0.45~1.12, P<0.01), CD3 (SMD=1.68, 95%CI:1.40~1.95, P<0.01), CD8 (SMD=-0.40, 95%CI:-0.64~-0.15, P<0.01), CD4 (SMD=-0.45, 95%CI:-0.73~-0.18, P<0.01), CD4/CD8 (SMD=-0.52, 95%CI:-0.85~-0.20, P<0.01), better than single chemo-therapy group, and the difference had statistical meaning (P<0.01). ConclusionActivating-blood resolving-stasis method joined with chemotherapy in the treatment of advanced gastric cancer is superior to the conventional therapy in lifting clinical effects, improving immune condition and relieving adverse reaction.

相似文献/References:

[1]杨有文.活血化瘀治疗脑挫裂伤的临床研究[J].西部中医药,2013,26(10):92.
　YANG Youwen.Clincal Study on Treatment for Contusion and Lacteration of Brain with the Method of Activating Blood and Removing Stasis[J].Western Journal of Traditional Chinese Medicine,2013,26(09):92.
[2]李艳梅,宋立中,万红棉,等.针药并用治疗高血压病肝热血瘀证疗效观察[J].西部中医药,2018,31(09):117.
　LI Yanmei,SONG Lizhong,WAN Hongmian,et al.Clinical Observation on Treating Hypertension of Liver-heat and Blood Stasis Pattern by Combination of Acupuncture and Medicines[J].Western Journal of Traditional Chinese Medicine,2018,31(09):117.
[3]张小荣,杨涛.李妍怡教授活血化瘀学术思想探讨[J].西部中医药,2016,29(02):47.
　ZHANG Xiaorong,YANG Tao.Preliminary Exploration on Professor Li Yanyi′s Academic Thinking of Promoting Blood Circulation and Eliminating Blood Stasis[J].Western Journal of Traditional Chinese Medicine,2016,29(09):47.
[4]于子凯,付长庚,吴永健,等.冠状动脉微血管疾病的中西医结合研究进展[J].西部中医药,2019,32(05):135.
　YU Zikai,FU Changgeng,WU Yongjian,et al.Research Progress of Combined Therapy of Chinese and Western Medicine for Coronary Microvascular Disease[J].Western Journal of Traditional Chinese Medicine,2019,32(09):135.
[5]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(09):149.
[6]贾继昌.王兰娣运用杏苏二陈汤治疗慢性阻塞性肺疾病经验[J].西部中医药,2020,33(03):56.[doi:10.12174/j.issn.1004-6852.2020.03.15]
　JIA Jichang Director: WANG Landi.Chief Physician Wang Landi′s Experience in Treating COPD by Xingsu Erchen Tang[J].Western Journal of Traditional Chinese Medicine,2020,33(09):56.[doi:10.12174/j.issn.1004-6852.2020.03.15]
[7]翟宇瑶,段万里,胡斌,等.活血化瘀类中药注射剂临床应用合理性分析[J].西部中医药,2021,34(05):112.[doi:10.12174/j.issn.2096-9600.2021.05.28]
　ZHAI Yuyao,DUAN Wanli,HU Bin,et al.An Analysis of Clinical Application Rationality of TCM Injection for Blood-activating Stasis-removing[J].Western Journal of Traditional Chinese Medicine,2021,34(09):112.[doi:10.12174/j.issn.2096-9600.2021.05.28]
[8]陈彩凤,胡振斌,黄家程,等.活血化瘀法治疗肝纤维化的研究进展[J].西部中医药,2022,35(12):166.[doi:10.12174/j.issn.2096-9600.2022.12.39]
　CHEN Caifeng,HU Zhenbin,HUANG Jiacheng,et al.Advances in Blood-activating Stasis-resolving Method in the Treatment of Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(09):166.[doi:10.12174/j.issn.2096-9600.2022.12.39]

备注/Memo

备注/Memo:
邵文博（1998—），男，在读硕士研究生。研究方向：肿瘤内科疾病的中西医结合治疗。北京市自然科学基金面上项目（7212194）
更新日期/Last Update: 2024-09-15